Last reviewed · How we verify
NCT05514015
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
Phase 4 trial testing rituximab combined with corticosteroids in Primary Membranous Nephropathy in 78 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | First Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 78 |
| Start date | 29 March 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- rituximab combined with corticosteroids — full drug profile →
- rituximab — full drug profile →
Conditions studied
- Primary Membranous Nephropathy — all drugs for Primary Membranous Nephropathy →
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Who can join
Adults 18 to 75, any sex, with Primary Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by \> 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05514015
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Membranous Nephropathy
Currently open trials in the same condition.
- NCT07204275 — A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropat · Phase 2, PHASE3 · recruiting
- NCT07157787 — Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) · Phase 2 · recruiting
- NCT06962800 — A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropath · Phase 3 · recruiting
- NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
- NCT06893328 — A Real World Study About PMN · recruiting
Other First Affiliated Hospital, Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07322835 — Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China · not yet recruiting
- NCT07322848 — DEB-TACE vs cTACE in HCC After TIPS · Phase 3 · recruiting
- NCT07087418 — AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases · recruiting
- NCT07014475 — Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI · not yet recruiting
- NCT06951334 — Clinical Trial of Vildagliptin in Early Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05514015 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital, Sun Yat-Sen University
- Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05514015.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing